stoxline Quote Chart Rank Option Currency Glossary
Exelixis, Inc. (EXEL)
22.81  0.16 (0.71%)    04-12 16:00
Open: 22.7
High: 23.045
Volume: 1,909,934
Pre. Close: 22.65
Low: 22.63
Market Cap: 6,916(M)
Technical analysis
2024-04-12 4:49:09 PM
Short term     
Mid term     
Targets 6-month :  27.21 1-year :  28.11
Resists First :  23.29 Second :  24.06
Pivot price 23.48
Supports First :  22.04 Second :  18.34
MAs MA(5) :  23.24 MA(20) :  23.47
MA(100) :  22.42 MA(250) :  21.17
MACD MACD :  0.1 Signal :  0.3
%K %D K(14,3) :  36.4 D(3) :  51.4
RSI RSI(14): 46.1
52-week High :  24.34 Low :  18.07
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EXEL ] has closed above bottom band by 2.0%. Bollinger Bands are 31.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 23.06 - 23.17 23.17 - 23.29
Low: 22.36 - 22.48 22.48 - 22.6
Close: 22.62 - 22.81 22.81 - 23
Company Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Headline News

Sat, 13 Apr 2024
Exelixis (NASDAQ:EXEL) Stock Price Down 3.9% - Defense World

Sat, 13 Apr 2024
Arizona State Retirement System Has $1.92 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Thu, 11 Apr 2024
Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study - Yahoo Movies UK

Thu, 11 Apr 2024
Exelixis stock slips as Barclays downgrades (NASDAQ:EXEL) - Seeking Alpha

Thu, 11 Apr 2024
Q1 2024 Earnings Forecast for Exelixis, Inc. (NASDAQ:EXEL) Issued By Zacks Research - Defense World

Thu, 04 Apr 2024
Exelixis, Inc.'s (NASDAQ:EXEL) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 303 (M)
Shares Float 256 (M)
Held by Insiders 2.3 (%)
Held by Institutions 88.2 (%)
Shares Short 8,250 (K)
Shares Short P.Month 8,370 (K)
Stock Financials
EPS 0.64
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.48
Profit Margin 11.3 %
Operating Margin 17 %
Return on Assets (ttm) 3.5 %
Return on Equity (ttm) 8.7 %
Qtrly Rev. Growth 13.1 %
Gross Profit (p.s.) 0
Sales Per Share 6.03
EBITDA (p.s.) 0.64
Qtrly Earnings Growth 0 %
Operating Cash Flow 333 (M)
Levered Free Cash Flow 125 (M)
Stock Valuations
PE Ratio 35.09
PEG Ratio 1
Price to Book value 3.04
Price to Sales 3.77
Price to Cash Flow 20.74
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android